767 related articles for article (PubMed ID: 29273067)
21. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
van der Heijde D; Cheng-Chung Wei J; Dougados M; Mease P; Deodhar A; Maksymowych WP; Van den Bosch F; Sieper J; Tomita T; Landewé R; Zhao F; Krishnan E; Adams DH; Pangallo B; Carlier H;
Lancet; 2018 Dec; 392(10163):2441-2451. PubMed ID: 30360964
[TBL] [Abstract][Full Text] [Related]
22. Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5.
Huang F; Sun F; Wan WG; Wu LJ; Dong LL; Zhang X; Kim TH; Sengupta R; Šenolt L; Wang Y; Qiu HM; Porter B; Haemmerle S
Chin Med J (Engl); 2020 Nov; 133(21):2521-2531. PubMed ID: 32925287
[TBL] [Abstract][Full Text] [Related]
23. Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study.
Pavelka K; Kivitz AJ; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Wang Y; Porter BO; Stefanska A; Richards HB; Rohrer S;
ACR Open Rheumatol; 2020 Feb; 2(2):119-127. PubMed ID: 31957970
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
van der Heijde D; Kivitz A; Schiff MH; Sieper J; Dijkmans BA; Braun J; Dougados M; Reveille JD; Wong RL; Kupper H; Davis JC;
Arthritis Rheum; 2006 Jul; 54(7):2136-46. PubMed ID: 16802350
[TBL] [Abstract][Full Text] [Related]
25. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.
van der Heijde D; Gensler LS; Deodhar A; Baraliakos X; Poddubnyy D; Kivitz A; Farmer MK; Baeten D; Goldammer N; Coarse J; Oortgiesen M; Dougados M
Ann Rheum Dis; 2020 May; 79(5):595-604. PubMed ID: 32253184
[TBL] [Abstract][Full Text] [Related]
26. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study.
Baraliakos X; Borah B; Braun J; Baeten D; Laurent D; Sieper J; Emery P; McInnes IB; van Laar JM; Wordsworth P; Wollenhaupt J; Kellner H; Colin L; Vandenhende F; Radford K; Hueber W
Ann Rheum Dis; 2016 Feb; 75(2):408-12. PubMed ID: 26248638
[TBL] [Abstract][Full Text] [Related]
27. Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study.
Blanco FJ; Möricke R; Dokoupilova E; Codding C; Neal J; Andersson M; Rohrer S; Richards H
Arthritis Rheumatol; 2017 Jun; 69(6):1144-1153. PubMed ID: 28217871
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS).
Baraliakos X; Østergaard M; Gensler LS; Poddubnyy D; Lee EY; Kiltz U; Martin R; Sawata H; Readie A; Porter B;
Clin Drug Investig; 2020 Mar; 40(3):269-278. PubMed ID: 31983056
[TBL] [Abstract][Full Text] [Related]
29. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
Baeten D; Østergaard M; Wei JC; Sieper J; Järvinen P; Tam LS; Salvarani C; Kim TH; Solinger A; Datsenko Y; Pamulapati C; Visvanathan S; Hall DB; Aslanyan S; Scholl P; Padula SJ
Ann Rheum Dis; 2018 Sep; 77(9):1295-1302. PubMed ID: 29945918
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.
Genovese MC; Durez P; Richards HB; Supronik J; Dokoupilova E; Mazurov V; Aelion JA; Lee SH; Codding CE; Kellner H; Ikawa T; Hugot S; Mpofu S
Ann Rheum Dis; 2013 Jun; 72(6):863-9. PubMed ID: 22730366
[TBL] [Abstract][Full Text] [Related]
31. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN).
Sieper J; Braun J; Kay J; Badalamenti S; Radin AR; Jiao L; Fiore S; Momtahen T; Yancopoulos GD; Stahl N; Inman RD
Ann Rheum Dis; 2015 Jun; 74(6):1051-7. PubMed ID: 24550171
[TBL] [Abstract][Full Text] [Related]
32. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
[TBL] [Abstract][Full Text] [Related]
33. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2.
Marzo-Ortega H; Sieper J; Kivitz A; Blanco R; Cohen M; Delicha EM; Rohrer S; Richards H
RMD Open; 2017; 3(2):e000592. PubMed ID: 29435364
[TBL] [Abstract][Full Text] [Related]
34. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Mease PJ; McInnes IB; Kirkham B; Kavanaugh A; Rahman P; van der Heijde D; Landewé R; Nash P; Pricop L; Yuan J; Richards HB; Mpofu S;
N Engl J Med; 2015 Oct; 373(14):1329-39. PubMed ID: 26422723
[TBL] [Abstract][Full Text] [Related]
35. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
McInnes IB; Mease PJ; Kirkham B; Kavanaugh A; Ritchlin CT; Rahman P; van der Heijde D; Landewé R; Conaghan PG; Gottlieb AB; Richards H; Pricop L; Ligozio G; Patekar M; Mpofu S;
Lancet; 2015 Sep; 386(9999):1137-46. PubMed ID: 26135703
[TBL] [Abstract][Full Text] [Related]
36. Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study.
Deodhar A; Shiff NJ; Gong C; Chan EKH; Hsia EC; Lo KH; Akawung A; Kim L; Xu S; Reveille JD
Rheumatol Ther; 2023 Aug; 10(4):983-999. PubMed ID: 37322274
[TBL] [Abstract][Full Text] [Related]
37. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
McInnes IB; Mease PJ; Ritchlin CT; Rahman P; Gottlieb AB; Kirkham B; Kajekar R; Delicha EM; Pricop L; Mpofu S
Rheumatology (Oxford); 2017 Nov; 56(11):1993-2003. PubMed ID: 28968735
[TBL] [Abstract][Full Text] [Related]
38. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis.
Sieper J; van der Heijde D; Dougados M; Maksymowych WP; Scott BB; Boice JA; Berd Y; Bergman G; Curtis S; Tzontcheva A; Huyck S; Weng HH
Arthritis Rheumatol; 2015 Oct; 67(10):2702-12. PubMed ID: 26139307
[TBL] [Abstract][Full Text] [Related]
39. Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial.
Li Q; Li L; Bi L; Xiao C; Lin Z; Cao S; Liao Z; Gu J
Trials; 2016 Jul; 17(1):337. PubMed ID: 27449221
[TBL] [Abstract][Full Text] [Related]
40. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
Mease P; van der Heijde D; Landewé R; Mpofu S; Rahman P; Tahir H; Singhal A; Boettcher E; Navarra S; Meiser K; Readie A; Pricop L; Abrams K
Ann Rheum Dis; 2018 Jun; 77(6):890-897. PubMed ID: 29550766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]